Tissue Inhibitor of Metalloproteinases 2 Level in Patients Undergoing Cardiac Surgery

Tissue Inhibitor of Metalloproteinases 2 Level Predicts Acute Kidney Injury in Patients Undergoing Cardiac Surgery

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06871826

Enrollment

100

Registered

2025-03-12

Start date

2023-07-22

Completion date

2025-01-25

Last updated

2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Extracorporeal Circulation; Complications, Surgery

Brief summary

Acute kidney injury (AKI) is one of the most frequent major complications in patients undergoing cardiac surgery. CSA-AKI is independently related to increased perioperative mortality, increased hospital and ICU length of stay as well as heath care expenditure. Identification of relevant biomarkers may lead to early diagnosis and improve patient outcomes and health care costs. The pathophysiology of CSA-AKI is complex and ischemia-reperfusion injury is one of the important factors. Recently, it has been shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP2) is associated with ischemia-reperfusion injury. In this study, relationship between TIMP2 with the risk of CSA-AKI was analyzed and the predictive value of elevated level of TIMP2 for early prediction of CSA-AKI was further evaluated.

Interventions

DRUGTIMP2 level

different TIMP2 level after on-pump cardiac surgery

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

TIMP2 level

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients (≥18 years old) underwent on-pump cardiac surgery * admitted to ICU immediately after surgery

Exclusion criteria

* Patients younger than 18 years * with prior AKI * end-stage kidney disease * need for chronic hemodialysis * pregnant patients * unable to give written consent for participation

Design outcomes

Primary

Measure	Time frame	Description
the development of CSA-AKI	1 Week	the development of CSA-AKI

Secondary

Measure	Time frame	Description
AKI severity	1 Week	AKI stage 1，stage 2，stage 3
need for RRT	1 Week	Reflect kidney function
duration of AKI (≥7 days)	1 Week	Reflect kidney function
length of ICU stay	up to 28 days	Reflect patient prognosis
post-operative hospital stay	up to 28 days	Reflect patient prognosis

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026